ChemRar, a Russian pharmaceutical research company, has announced the successful completion of the second phase of clinical trials of a new domestic drug effective against type A and B flu strains, including those resistant to other drugs.
As the employee of the Department of Innovative Pharmaceuticals, Medical Technology and Biotechnology at the Moscow Institute of Physics and Technology, Director for Development of ChemRar Aslan Pshikhachev said that this is the first domestic influenza drug, which in terms of a number of characteristics, including effectiveness, significantly exceeds world analogs.
The Russian molecule, patented in all countries and having passed the necessary preclinical stages, as well as the first and second phases of clinical trials, does not yet have a commercial name and is designated as AB5080.
The test of the effectiveness of AB5080 in the second phase of clinical trials was carried out on 135 volunteer patients and showed a high degree of safety and good tolerability. In the near future, the third final phase of clinical trials involving a large group of patients will be carried out.